RxDoctor Payments Data

Kathleen Glaspy, MD

Internal Medicine · Orange, CANPI 1134311186

Payments from drug & device makers

$266in general payments, 2019–2025

Across 10 payments — averaging $26.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$97
  • Astellas Pharma US Inc$38
  • Teva Pharmaceuticals USA, Inc.$28
  • Vertical Pharmaceuticals, LLC$22
  • Pfizer$21
  • E.r. Squibb & Sons, L.L.C.$18
  • plus $43 from 3 others

What the payments were for

  • Consulting fees$124%
  • Food & beverage$25496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$266 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$80,415
Medicare patients
205
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$151,455
EliquisApixaban58$57,287
JardianceEmpagliflozin39$54,183
FarxigaDapagliflozin Propanediol27$40,889
Repatha SureclickEvolocumab43$34,428
TrulicityDulaglutide26$33,240
MounjaroTirzepatide29$31,974
JanuviaSitagliptin Phosphate19$27,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,998
LinzessLinaclotide25$17,892
MyrbetriqMirabegron11$11,269
Atorvastatin Calcium715$8,971
Wixela InhubFluticasone Propion/Salmeterol51$8,500
Losartan Potassium495$6,994
Breo ElliptaFluticasone/Vilanterol14$6,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$97$65,21455 claims
PfizerEliquis$21$57,28758 claims
AstraZenecaFarxiga$13$40,88927 claims
GSKTrelegy Ellipta, Breo Ellipta$18$31,70448 claims
Astellas Pharma US IncMyrbetriq$38$11,26911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →